普洛藥業(000739.SZ):康裕製藥的司美格魯肽注射液體重管理和成人2型糖尿病適應症的臨牀試驗申請獲批
格隆匯1月2日丨普洛藥業(000739.SZ)公佈,近日,普洛藥業股份有限公司控股子公司浙江普洛康裕製藥有限公司(簡稱“康裕製藥”)收到國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》(通知書編號:2024LP02958、2024LP02959、2024LP02960、2024LP02961、2024LP02962、2024LP02963、2024LP02964),康裕製藥申報的司美格魯肽注射液體重管理和成人2型糖尿病適應症的臨牀試驗申請獲得批准。
司美格魯肽是一種長效胰高血糖素樣肽-1(GLP-1)受體激動劑,可選擇性地結合並激活GLP-1受體。GLP-1是一種通過GLP-1受體介導而對葡萄糖代謝產生多種作用的生理激素。司美格魯肽通過刺激胰島素分泌和降低胰高血糖素分泌的機制來降低血糖。GLP-1也是食慾和熱量攝入的生理調節因子,GLP-1受體存在於大腦中與食慾調節相關的幾個區域。司美格魯肽通過增加飽感和飽腹感從而降低食慾,同時降低飢餓感和預期攝食量,從而達到減重作用。
截至公吿披露日,司美格魯肽注射液累計投入的研發費用為人民幣1,920.3萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.